Research discussing potential therapeutic coronavirus targets
Published and Preprint Papers
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
The SARS-CoV-2 main protease M pro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells.
A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing
Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort.
A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19.